FDA
-
-
-
-
-
-
-
Schrödinger Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results
-
-
-
-
-
-
-
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event
-
-
-
-
-
-
-
Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor
-
-
-
-
-
-
-
Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update
-
-
-
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

